Tolerance, Pharmacokinetics / Pharmacodynamics (PK / PD) and Immunogenicity of Pegylated Uric Acid Oxidase for Injection in Healthy Adults and Hyperuricemia Volunteers

Inclusion Criteria: * Healthy volunteers: * Subjects understand well trial purpose, nature, content, process and possible adverse reactions, and voluntarily sign an informed consent form. * Serum uric acid level\<360 µ mol / L twice on different days. * Healthy male or female aged between 18 and 60 years old (including the critical value). * The body mass index is in the range of 18-30kg/m2 (including the critical value). The weight of male is not less than 50 kg, and that of female is not less than 45 kg (including the critical value). * Subjects who had not any medical history of cardiovascular, digestive, respiratory, nervous, haemal diseases or hepatic/renal impairment.The following examination show that the indicators are normal or abnormal without clinical significance. The examination including: physical examination, 12-lead ECG, vital sign measurements and laboratory safety tests . * The subjects have no family planning within 6 months and could select contraceptive method. They have no sperm and egg donation program. * Before the study, all subjects have been informed of the study's purpose, protocal, benefits, and risks, and signed the informed consent voluntarily. * The blood pregnancy test of female subjects was negative, the menstrual cycle was regular, and the menstrual bleeding period was 3 \~ 7 days. Patients with hyperuricemia: * Patients with hyperuricemia ,male or female aged between 18 and 60 years old (including the critical value). * Stop uric acid lowering treatment for at least 7 days, and 480≤UA≤540µmol/L twice on different days within 7 days. * The body mass index is in the range of 18-30kg/m2 (including the critical value). The weight of male is not less than 50 kg, and that of female is not less than 45 kg (including the critical value). * Before the study, all subjects have been informed of the study's purpose, protocal, benefits, and risks, and signed the informed consent voluntarily. * The blood pregnancy test of female subjects was negative, the menstrual cycle was regular, and the menstrual bleeding period was 3 \~ 7 days. Exclusion Criteria: * Healthy volunteers: * A history of drug allergy, or allergic allergic disease, or known to be allergic to the test drug or its excipients or the same type of drug; * Hepatitis (including hepatitis B and C), positive screening results for AIDS or syphilis; * Any history of acute or chronic illness that might affect drug absorption, and/or metabolism; * Any history of drug abuse in the past 12 months prior to screening; * Any history of alcohol abuse 3 months prior to screening or moderate drinkers (drink more 2 units per day or 14 units per week); * Smoking more than 5 cigarettes per day during the 3 months prior to screening; * Blood donation, massive blood loss (#400mL) or enrolled in other clinical trials 3 months prior to screening; * Any use of other prescription drugs (including contraceptive)#over-the counter drugs, Chinese herbal medicine, health care products and 14 days prior to medication for this study; * Any history of postural hypotension, syncope, or amaurosis; * 6-glucose phosphate dehydrogenase (G6PD) deficiency; * Lactating or pregnant women Patients with hyperuricemia: * Using uric acid lowering drugs and unwilling to stop existing drugs. * Ultrasonic examination of the metatarsal-toe joint suggested the presence of tophi. * Serum CA72-4 level ≥7.5U / mL. * History of organic heart disease (symptomatic cardiac insufficiency with grade II-IV). * Patients with refractory hypertension. * Patients with malignant tumors (treatment or not). * Patients with organ transplantation treated with immunosuppressants. * Any history of drug abuse in the past 12 months prior to screening; * Any history of alcohol abuse 3 months prior to screening or moderate drinkers (drink more 2 units per day or 14 units per week). * Smoking more than 5 cigarettes per day during the 3 months prior to screening. * A history of drug allergy, or allergic allergic disease, or known to be allergic to the test drug or its excipients or the same type of drug. * Any history of acute or chronic illness that might affect drug absorption, and/or metabolism. * 6-glucose phosphate dehydrogenase (G6PD) deficiency. * Once treated with urate oxidase. * Subjects had an uncorrected dehydration, acidosis, hypotension, renal insufficiency, or were using drugs with nephrotoxicity.